Ad hoc: Biofrontera AG: Clinical study with BF-derm1 shows efficacy in severe chronic
urticaria
(Thomson Reuters ONE) - Biofrontera AG / Misc. matters / Ad hoc: Clinical study with BF-derm1 shows efficacy in severe chronicurticaria Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------Leverkusen, Germany, 27 July 2009 - Biofrontera AG today announcesthat it has received the results of an adaptive phase II study withBF-derm1 in chronic urticaria patients who cannot be sufficientlytreated with current medication. The study has demonstrated very goodefficacy and safety for the orally available BF-derm1 tablets.The adaptive trial was composed of three parts. Positive interimreports were already reported for the two initial parts. These firstparts mostly served to determine the dosis of the active compound forthe third part of the trial, in which the efficacy and safety ofBF-derm1 was evaluated. Since the two higher concentrations showedthe best effects during the 8-week treatment period, the highestconcentration was used in the ultimate part of the trial.In its entirety the study has demonstrated that BF-derm1 alleviatesthe symptoms of severe chronic urticaria and concomitantlyconsiderably reduces the intake of sedating antihistaminicco-medication. To the contrary, patients treated with a placebomedication took increasing amounts of antihistaminics to ease theirsymptoms during the course of the study. The most frequent sideeffects were sedation and headache, which were, however, notdose-related and also occurred in the placebo group.On the basis of these positive results Biofrontera intends to find alicense partner for its product candidate BF-derm1. The clinicaldevelopment of this promising product candidate will then becontinued jointly.Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, GermanyISIN: DE0006046113, WKN: 604611Contact:Anke zur MühlenBiofrontera AGTel.: +49 (0214) 87 63 222Fax.: +49 (0214) 87 63 290E-mail: a.zurmuehlen(at)biofrontera.com --- End of Message ---Biofrontera AGHemmelrather Weg 201 Leverkusen GermanyWKN: 604611; ISIN: DE0006046113; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Open Market in Frankfurter Wertpapierbörse, Regulierter Markt in Börse Düsseldorf;
Datum: 27.07.2009 - 15:46 Uhr
Sprache: Deutsch
News-ID 4005
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 216 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ad hoc: Biofrontera AG: Clinical study with BF-derm1 shows efficacy in severe chronic
urticaria"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
